Clinical Trial Search

Primary: Mean Low Density Lipid-Cholesterol (LDL-C) Levels in High and Very High Risk Cardiovascular Participants — 2.40; 1.99 mmol/L

Primary: Percent Change From Baseline in LDL-C at Week 6 — -26.7; -12.8 Percent Change — p=<0.001

Primary: Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I) — -24.8; -10.1; -13.8 Percentage Change — p=<0.001

Primary: Serum LDL Cholesterol — 122.2; 113.5 mg/dl

Primary: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay — -47.35; -81.57; -85.71; 0.48 Percent change — p=<.001

Primary: Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C — -27.4; -11.0 Percent Change — p=<0.001

Primary: Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 6 — -48.97; -27.75 percentage change — p=<0.0001

Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — 1.0; -54.9 percent change — p=<0.001

Primary: Percentage of Participants Achieving Target Lipid Values — 46.8 Percentage of participants

Primary: Change in Blood LDL Cholesterol Level — -32.48; 2.54 mg/dL — p=<0.0001

Primary: Number of Participants Achieving Individual LDL Cholesterol (LDL-C) Target Level — 678 Participants

Primary: Reduction of LDL Cholesterol Levels — -39.45; -29.13 percent change of LDL — p=0.0013

Primary: Changes in Plaque Architecture and Composition Directly Measured by Magnetic Resonance Imaging (MRI) in the Aorta and Carotid Arteries — 7; 5 percentage of internal…

Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point — -3.4; -40.2 percentage of baseline — p=<0.001

Primary: Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12 — 1.0; -55.6 percent change — p=<0.001

Primary: Percentage of Participants Achieving LDL Level Less Than or Equal to (≤) 100 mg/dL at the 6 Month Visit — 51.52 percentage of participants

Primary: Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis — -20.3; -56.0 percent change — p=<0.0001

Primary: Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE) — 819; 927 Participants — p=0.004

Primary: Number of Participants With Post-index Cardiovascular (CV) Events — 700; 1012 Participants — p=<0.001

Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -0.8; -50.8 percent change — p=<0.001

Primary: Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs) — 109 Participants

Primary: Cholesteryl Ester Fractional Clearance Rate

Primary: Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6 — -30.8; -10.9 Percent — p=<0.001

Primary: Total Cholesterol Before and After Simvastatin/Ezetimibe Administration — 255; 253; 180; 215 mg/dl — p=<0.05

Primary: LDL Goal Attainment — 6; 6; 9 participants

Primary: Total Cholesterol (TC) Levels at First Acute Coronary Event — 163.5 mg/dL

Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001

Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12 — 0.27; 3.91; -73.70; -69.98 percent change — p=<0.001

Primary: Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand) — 8.8; -29.7; -44.0; -47.2 Percent…

Primary: Myocardial Perfusion at Rest — 55; 135 IU/s